miplyffa
Generic: arimoclomol
miplyffa: developed by 2 companies · 1 FDA decision. Updated within the last hour.
Development Pipeline (3)
| Company | Phase |
|---|---|
| XOMA Royalty Corporation (XOMA) | Approved |
| XOMA Royalty Corporation (XOMA) | — |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | Approved |
FDA Decisions
FDA_MeetingThe FDA Genetic Metabolic Diseases Advisory Committee voted 11-5 that data support arimoclomol is effective in the treatment of patients with Niemann-Pick disease type C.(ZVRA)
Frequently asked questions
Who is developing miplyffa?
miplyffa is being developed by XOMA Royalty Corporation, ZEVRA THERAPEUTICS, INC..
What is miplyffa's latest FDA decision?
The most recent tracked FDA decision for miplyffa is FDA_Meeting for The FDA Genetic Metabolic Diseases Advisory Committee voted 11-5 that data support arimoclomol is effective in the treatment of patients with Niemann-Pick disease type C., dated August 2, 2024.
Get deeper analysis on miplyffa
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis